Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity

Journal of Cellular Biochemistry

Volumn 98, Issue 1, 2006, Pages 128-138

  Yang, Heng Yin ^a   Yang, Huiling ^a,c   Zhao, Ruiying ^a,b   Lee, Mong Hong ^a,b,d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

HER2; JAB1; p27; SKP2; Tumor suppression

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; THREONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION SYSTEM; MITOGENESIS; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; UBIQUITINATION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE DELETION; GROWTH INHIBITORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MITOGENS; NIH 3T3 CELLS; PEPTIDE HYDROLASES; PROTEIN BINDING; RECEPTOR, ERBB-2; THREONINE; TRANSFECTION;

ANIMALIA;

EID: 33646021967     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20762     Document Type: Article

References (40)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831.
2. Carrano AC, Eytan E, Hershko A, Pagano M. 1999. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199.
3. Clurman BE, Porter a P. 1998. New insights into the tumor suppression function of P27(Kip1). Proc Natl Acad Sci USA 95:15158-15160.
4. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. 2003. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 9:5652-5659.
5. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. 1998. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180.
6. Fujita N, Sato S, Katayama K, Tsuruo T. 2002. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277:28706-28713.
7. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547-5551.
8. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, Hershko A. 2001. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91: 1745-1751.
9. Hung SJMaM-C. 1995. Regulation of HER2/neu gene expression. Oncology Reports 2:497-503.
10. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93:10933-10938.
11. Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, Malek NP. 2004. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 18: 2602-2607.
12. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. 2003. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 63:2977-2981.
13. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. 2000. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223.
14. Laronga C, Yang HY, Neal C, Lee MH. 2000. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275:23106-23112.
15. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC, Jr. 2000. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6:260-270.
16. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC, Jr. 2003. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278:23441-23450. Epub 2003 Apr 16.
17. Lee MH, Reynisdottir I, Massague J. 1995. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649.
18. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. 2002. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8:1153-1160.
19. Lim MS, Adanison A, Lin Z, Perez-Ordonez B, Jordan RC, Tripp S, Perkins SL, Elenitoba-Johnson KS. 2002. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: Correlation with p27(Kip1) and proliferation index. Blood 100:2950-2956.
20. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Mori M. 2002. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: Modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62:3819-3825.
21. Nakayama KI, Nakayama K. 2005. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 16:323-333.
22. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Hatakeyama S. 2000. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 19:2069-2081.
23. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI. 2004. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 6:661-672.
24. Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH. 2001. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 30:169-175.
25. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251.
26. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, Chau V. 2000. A nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 97:4579-4584.
27. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
28. Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, Medeiros LJ. 2003. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 9:1121-1128.
29. Reardon DB, Hung MC. 1993. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene. J Biol Chem 268:18136-18142.
30. Reynisdottir I, Polyak K, Iavarone A, Massague J. 1995. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes & Development 9:1831-1845.
31. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 8:1145-1152.
32. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H. 2003. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 65:355-362.
33. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. 2002. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110:633-641.
34. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
35. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, Tokuda M. 2001. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7:4130-4135.
36. Tomoda K, Kubota Y, Kato J. 1999. Degradation of the cyclin-dependent- kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160-165.
37. Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato JY. 2004. Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem 279:43013-43018. Epub 2004 Aug 6.
38. Kip1 pKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8:1136-1144.
39. Yang HY, Zhou BP, Hung MC, Lee MH. 2000. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 275:24735-24739.
40. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. 2000. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031.